>latest-news

BioXcel Therapeutics’ AI Innovation Redefines Drug Repurposing

BioXcel uses AI to repurpose shelved drugs, speeding development and reducing costs, notably treating agitation in schizophrenia and bipolar disorder.

Breaking News

  • Jun 13, 2024

  • Mrudula Kulkarni

BioXcel Therapeutics’ AI Innovation Redefines Drug Repurposing

BioXcel Therapeutics is a leading biopharmaceutical company has made a groundbreaking move within the pharmaceutical industry. The company is the driving force behind the revolutionary approach to the development of drug though the power of AI. The innovative platform of the company is breathing new life into shelved drugs, having enough potential to unlock treasure trove untapped therapeutic possibilities.

Normally, the process of developing drugs is an arduous & expensive process, which often takes several years and requires consistent financial investment. However, BioXcel is challenging this paradigm by leveraging the capabilities of AI to accelerate the identification and development of novel drug candidates.

At the heart of BioXcel's strategy is its proprietary platform, which makes use of Artificial Intelligence and big data analytics to sift through vast amounts of biomedical information. By studying the data related to drug compounds, clinical outcomes & disease pathways, the AI-driven platform can recognize promising candidates for repurposing drugs. These are the drugs that have been previously shelved or failed in clinical trials for one indication but might also hold potential for treating other conditions.

This particular approach not only tends to speed the process the drug development but also reduces expenses, because repurposing existing drugs eliminates the requirement for extensive preclinical and early-stage clinical testing. Moreover, it also provides a more sustainable and environmentally friendly approach to drug discovery by reducing the need for resource-intensive research and development activities.One of BioXcel's most notable successes to date is the repurposing of a shelved drug for the treatment of acute agitation in patients with schizophrenia and bipolar disorder. With the help of their AI-driven platform, the company was successful in identifying a compound that has the potential to address this unrecognised medical need, leading to the initiation of clinical trials and promising early results.

As BioXcel continues to blaze a trail in the field of AI-powered drug development, the pharmaceutical industry stands on the brink of a transformative shift — one that promises to deliver effective treatments to patients in need while also advancing the process of drug discovery.

 

Ad
Advertisement